AU2020396868A1 - Targeted transfer RNAS for treatment of diseases - Google Patents

Targeted transfer RNAS for treatment of diseases Download PDF

Info

Publication number
AU2020396868A1
AU2020396868A1 AU2020396868A AU2020396868A AU2020396868A1 AU 2020396868 A1 AU2020396868 A1 AU 2020396868A1 AU 2020396868 A AU2020396868 A AU 2020396868A AU 2020396868 A AU2020396868 A AU 2020396868A AU 2020396868 A1 AU2020396868 A1 AU 2020396868A1
Authority
AU
Australia
Prior art keywords
trna
variant
engineered
sequence
engineered trna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020396868A
Other languages
English (en)
Inventor
Stephen BURLEIGH
David HUSS
Anupama Lakshmanan
Liana STEIN
Richard Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shape Therapeutics Inc
Original Assignee
Shape Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shape Therapeutics Inc filed Critical Shape Therapeutics Inc
Publication of AU2020396868A1 publication Critical patent/AU2020396868A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2020396868A 2019-12-02 2020-12-01 Targeted transfer RNAS for treatment of diseases Abandoned AU2020396868A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962942690P 2019-12-02 2019-12-02
US201962942667P 2019-12-02 2019-12-02
US62/942,667 2019-12-02
US62/942,690 2019-12-02
US202063010856P 2020-04-16 2020-04-16
US63/010,856 2020-04-16
US202063111856P 2020-11-10 2020-11-10
US63/111,856 2020-11-10
PCT/US2020/062671 WO2021113218A1 (en) 2019-12-02 2020-12-01 Targeted transfer rnas for treatment of diseases

Publications (1)

Publication Number Publication Date
AU2020396868A1 true AU2020396868A1 (en) 2022-07-14

Family

ID=74046150

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020396868A Abandoned AU2020396868A1 (en) 2019-12-02 2020-12-01 Targeted transfer RNAS for treatment of diseases

Country Status (6)

Country Link
EP (1) EP4069841A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023504661A (cg-RX-API-DMAC7.html)
CN (1) CN115397983A (cg-RX-API-DMAC7.html)
AU (1) AU2020396868A1 (cg-RX-API-DMAC7.html)
CA (1) CA3163514A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021113218A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004587A (es) 2017-11-02 2021-04-12 Univ Iowa Res Found Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt.
JP7712270B2 (ja) 2019-11-01 2025-07-23 テバード バイオサイエンシズ インコーポレイテッド 未成熟終止コドン媒介障害を処置するための方法および組成物
BR112022020780A2 (pt) 2020-04-14 2022-11-29 Flagship Pioneering Innovations Vi Llc Composições de trem e usos das mesmas
WO2023097268A2 (en) * 2021-11-23 2023-06-01 Mantra Bio, Inc. Extracellular vesicles comprising non-naturally occurring modular rna hairpins and uses thereof
WO2023220342A2 (en) 2022-05-13 2023-11-16 Shape Therapeutics Inc. Engineered tranfer rnas
WO2024149415A1 (en) * 2023-01-10 2024-07-18 Biologicke Centrum Av Cr, V. V. I. Altered trnas for treatment of genetic diseases caused by premature termination codon
WO2024197081A1 (en) * 2023-03-20 2024-09-26 Hc Bioscience, Inc. Minimally-sized dna threads for trna therapy
EP4442826A1 (en) 2023-04-06 2024-10-09 Universität Hamburg Synthetic dna construct encoding transfer rna
EP4458967A1 (en) 2023-05-02 2024-11-06 Universität Hamburg Pharmaceutical composition comprising multiple suppressor transfer rnas
TW202504646A (zh) * 2023-06-16 2025-02-01 北京大學 利用環狀rna抑制無義介導的降解的系統和方法
TW202521693A (zh) * 2023-08-11 2025-06-01 大陸商上海科動生物技術有限公司 工程化抑制性tRNA分子和方法
WO2026001270A1 (en) * 2024-06-24 2026-01-02 Zhuhai Codone Biotechnology Co., Ltd. Engineered trna molecules and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676810B2 (en) * 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2017070632A2 (en) * 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
CN110612353A (zh) * 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
MX2020004587A (es) * 2017-11-02 2021-04-12 Univ Iowa Res Found Métodos de rescate de codones de paro mediante reasignación genética con ace-arnt.
US10968257B2 (en) * 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
IL284878B2 (en) * 2019-01-18 2026-04-01 Flagship Pioneering Inc TREM preparations and their uses

Also Published As

Publication number Publication date
CN115397983A (zh) 2022-11-25
EP4069841A1 (en) 2022-10-12
JP2023504661A (ja) 2023-02-06
WO2021113218A1 (en) 2021-06-10
CA3163514A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
WO2021113218A1 (en) Targeted transfer rnas for treatment of diseases
US10968453B2 (en) Compositions for modulating SOD-1 expression
EP3288594B1 (en) Dual aav vector system for crispr/cas9 mediated correction of human disease
JP2021536244A (ja) 遺伝子操作されたadarのリクルートを介したrna及びdna塩基の編集
US20250270543A1 (en) Programmable rna editing in vivo via recruitment of endogenous adars
US20230383277A1 (en) Compositions and methods for treating glycogen storage disease type 1a
EP3403675B1 (en) Adeno-associated virus virion for use in treatment of epilepsy
JP2016517278A (ja) スタッファー/フィラーポリヌクレオチド配列を含むベクターおよびその使用方法
TW202027797A (zh) 用於治療α-1抗胰蛋白酶不足的組成物及方法
TW202304528A (zh) 用於治療遺傳疾病的體內核酸酶媒介的基因靶向之組成物及方法
CN117295819A (zh) 用于抑制补体组分3表达的组合物和方法
US20230165977A1 (en) Modified nucleic acids encoding aspartoacylase (aspa) and vector for gene therapy
JP2025175283A (ja) Amdの処置のためのhtra1調節
CN119630433A (zh) 基因疗法组合物及其使用方法
KR20210039495A (ko) 피드백이 가능한 합성 유전자, 표적 시드 매치 카세트, 및 그 용도
EP4665853A1 (en) Compositions for and methods of treating and/or preventing glutaric aciduria type-i
AU2023329830A1 (en) Engineered constructs for increased transcription of rna payloads
TW202338086A (zh) 有用於治療異染性白質失養症之組成物
JP2024530050A (ja) 中枢神経系に影響を及ぼす障害の改善された治療のための組成物及び方法
TW202208406A (zh) 用於治療kcnq4相關性聽力損失之組成物及方法
KR20230003554A (ko) 낮은 전사 활성을 갖는 프로모터를 사용하여 뉴클레아제 발현 및 표적-외 활성을 감소시키기 위한 조성물 및 방법
WO2024238584A1 (en) Engineered constructs with cassette arrangements for increased transcription of rna payloads
WO2024137991A2 (en) Engineered guide rnas and polynucleotides
WO2025096897A1 (en) Method for identifying and employing target site blocking oligonucleotides in the treatment of mef2c haploinsufficiency syndrome
WO2025227159A1 (en) Gene editing treatment for correcting splicing defect in familial dysautonomia

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period